Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Martin Kortuem

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Blood|February 9, 2013
CarfilzomibK Martin Kortuem, A Keith Stewart
Leukemia & Lymphoma|September 13, 2012
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myelomaYuan Xiao Zhu, K Martin Kortuem, A Keith Stewart
Presse Medicale (Paris, France : 1983)|December 11, 2024
Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: Where do we stand today?Xiang Zhou, K Martin Kortuem, Leo Rasche, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 26, 2014
Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myelomaK Martin Kortuem, Kaitlyn Zidich, Steven R Schuster, et al.
European Journal of Radiology|August 26, 2022
Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by <sup>18</sup>F-FDG and <sup>11</sup>C-methionine PET/CTAnke Heidemeier, Wiebke Schloetelburg, Annette Thurner, et al.
British Journal of Haematology|March 14, 2013
Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant diseaseJan B Egan, K Martin Kortuem, Ahmet Kurdoglu, et al.
Blood|June 11, 2014
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myelomaYuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, et al.
Plos One|February 8, 2014
Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangementsJan B Egan, Michael T Barrett, Mia D Champion, et al.
Leukemia Research|October 17, 2013
The clinical significance of cereblon expression in multiple myelomaSteven R Schuster, K Martin Kortuem, Yuan Xiao Zhu, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Blood|February 9, 2013
CarfilzomibK Martin Kortuem, A Keith Stewart
Leukemia & Lymphoma|September 13, 2012
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myelomaYuan Xiao Zhu, K Martin Kortuem, A Keith Stewart
Presse Medicale (Paris, France : 1983)|December 11, 2024
Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: Where do we stand today?Xiang Zhou, K Martin Kortuem, Leo Rasche, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 26, 2014
Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myelomaK Martin Kortuem, Kaitlyn Zidich, Steven R Schuster, et al.
European Journal of Radiology|August 26, 2022
Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by <sup>18</sup>F-FDG and <sup>11</sup>C-methionine PET/CTAnke Heidemeier, Wiebke Schloetelburg, Annette Thurner, et al.
British Journal of Haematology|March 14, 2013
Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant diseaseJan B Egan, K Martin Kortuem, Ahmet Kurdoglu, et al.
Blood|June 11, 2014
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myelomaYuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, et al.
Plos One|February 8, 2014
Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangementsJan B Egan, Michael T Barrett, Mia D Champion, et al.
Leukemia Research|October 17, 2013
The clinical significance of cereblon expression in multiple myelomaSteven R Schuster, K Martin Kortuem, Yuan Xiao Zhu, et al.
Pageof 1